Revisions to the CMS billing code system could be announced November 1, 2017, potentially impacting how biosimilars will compete with reference products.
Revisions to the CMS billing code system could be announced November 1, 2017, potentially impacting how biosimilars will compete with reference products.
The proposed CMS rule change could give every biosimilar its own Healthcare Common Procedure Coding System (HCPCS) (“J-code”). Currently, Medicare Part B pays for biosimilars under the Physician Fee Schedule (PFS) based on average sales price (ASP) of all biosimilar products within the same HCPCS code—biosimilar products with the same reference product are grouped together to calculate an ASP, and physicians are reimbursed the same amount for all biosimilars with the same reference product. The coding system for biosimilars is also separate from the coding system for their reference products, so that as a biosimilar’s price is reduced, the ASP also declines, which is the basis for reimbursement. However, the reference products’ ASPs remain unaffected.
A proposed CMS rule change was posted in July 2017 concerning current CMS payment policies under the PFS and other revisions to Medicare Part B for 2018. If a rule change occurs, it would apply beginning January 1, 2018.
Amanda Forys, MSPH, Director at Xcenda, notes that because Medicare will be such a large payer for biosimilars, coding and payment policy set forth by CMS will have a significant effect on the success, sustainability, and availability of biosimilars. CMS’s controversial decision to group biosimilars into single HCPCS codes can cause confusion among providers and create concerns around pharmacovigilance. In addition, the rule increases the administrative burden and claims processing delays and can inadvertently prompt physicians to continue using reference drugs because they have better clarity in their coding and billing guidance. “Ultimately, this scenario could limit patient access to products that could significantly reduce out-of-pocket payments for specialty medications,” Forys explains in her blog.
In comments submitted to CMS, industry group Pharmaceutical Research and Manufacturers of America (PhRMA) urged CMS to revise its biosimilar reimbursement policy to provide for separate HCPCS codes for each biosimilar and to reimburse each biosimilar based on its own ASP—this would encourage a robust competitive market for biosimilars and clinically appropriate, safe use of these medicines. The Biotechnology Innovations Organization (BIO) agreed, noting that this change would maximize patient safety and access to appropriate therapies and foster a competitive, innovative market for biosimilars.
The Biosimilars Council also recommended that each biosimilar be assigned its own code in the HCPCS system and be paid at a rate based on that biosimilar’s own ASP: “To have a level playing field, the Medicare payment rate for biosimilars should reflect the same approach applied to other nonsubstitutable products.” The group said that without a level playing field, it is doubtful biosimilars will be able to achieve the kind of success Congress envisioned when it passed the Biologics Price Competition and Innovation Act. Biosimilar maker Novartis also encouraged CMS to revise its reimbursement policy in the final rule to allow for distinct coding and payment for each biosimilar. “We request that CMS pay each biosimilar at 100% of its own individual ASP (plus a fixed percentage of the reference product’s ASP, as is already clearly established) and under its own HCPCS code,” the company said. “Such a policy would spur competition in the market and allow patients greater access to drugs at lower prices.”
Patient organizations including the Arthritis Foundation, the Cancer Support Community of Arizona, and the U.S. Pain Foundation asked CMS to end the blended reimbursement policy for biosimilars to help increase the number of biosimilar products available to patients.
QuintilesIMS also called on CMS to assign each biosimilar a unique HCPCS code rather than blending multiple biosimilars into a single code. “CMS’ current policy of using modifiers for biosimilars reimbursed under the same HCPCS code makes such data collection difficult,” the company wrote. “First, the use of these modifiers, which is unique to biosimilars, applies only to Medicare and not other payers. Thus, tracking of adverse events across different payers would prove challenging.”
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.